Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?

Ophthalmic technology companies Alcon Inc. and RxSight, Inc. have formed a strategic collaboration aimed at co-developing post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). This partnership combines RxSight's proprietary light-adjustable technology with Alcon's global commercial reach and surgical equipment portfolio, potentially reshaping the cataract and refractive surgery landscape.

Meanwhile, Alcon has bolstered its international presence by opening a second training center in partnership with the Aravind Eye Care System in India. This expansion provides enhanced access to phacoemulsification training and advanced eye care technology. Comparing the two companies' latest First Quarter 2026 financial reports, Alcon posted $2.7 billion in net sales, up 10% year-over-year, driven by surgical sales of $1.5 billion and Vision Care sales of $1.2 billion.

The company reported a strong core diluted earnings per share of $0.85 and a core operating margin of 21.2%. On the other hand, RxSight experienced an 18.5% drop in revenue to $30.9 million, primarily due to lower sales of its Light Delivery Devices. The company's net loss widened to $15.9 million for the quarter. While Alcon appears to be the more stable, lower-risk compounder with reliable margins and a global footprint, RxSight demonstrates strong revenue growth and a promising Light Adjustable Lens technology.